Clinical Trials Logo

Stage III Ureter Cancer AJCC v8 clinical trials

View clinical trials related to Stage III Ureter Cancer AJCC v8.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03617913 Completed - Clinical trials for Stage III Bladder Cancer AJCC v8

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Start date: September 19, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects of avelumab and how well it works in combination with fluorouracil and mitomycin or cisplatin and radiation therapy in treating participants with muscle-invasive bladder cancer. Monoclonal antibodies, such as avelumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as fluorouracil, mitomycin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Giving avelumab with chemotherapy and radiotherapy may work better in treating participants with muscle-invasive bladder cancer.

NCT ID: NCT03590054 Completed - Metastatic Melanoma Clinical Trials

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Start date: August 20, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the best dose and side effects of abexinostat and how well it works with given together with pembrolizumab in treating participants with microsatellite instability (MSI) solid tumors that have spread to other places in the body. Abexinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving abexinostat and pembrolizumab may work better in treating participants with solid tumors.

NCT ID: NCT00749892 Completed - Clinical trials for Stage IIIA Bladder Cancer AJCC v8

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

Start date: June 10, 2008
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well erlotinib hydrochloride works in Treating participants with muscle invasive urothelial cancer or urothelial cancer that has come back. Drugs used in chemotherapy, such as erlotinib hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.